Acknowledgement
The authors are grateful to Eiji Kashiyama and Ken Umehara for recommending the submission of this article.
References
- Satcher D (1995) Toxicological profile for dinitrophenols. U.S. Department of Health and Human Services, Agency for Toxic Substances and Disease Registry, Atlanta
- Cunha FM, Caldeira da Silva CC, Cerqueira FM, Kowaltowski AJ (2011) Mild mitochondrial uncoupling as a therapeutic strategy. Curr Drug Targets 12:783-789. https://doi.org/10.2174/138945011795528778
- Jastroch M, Keipert S, Perocchi F (2014) From explosives to physiological combustion: next generation chemical uncouplers. Mol Metab 3:86-87. https://doi.org/10.1016/j.molmet.2014.01.003
- Fu YY, Zhang M, Turner N, Zhang LN, Dong TC, Gu M, Leslie SJ, Li JY, Nan FJ, Li J (2013) A novel chemical uncoupler ameliorates obesity and related phenotypes in mice with diet-induced obesity by modulating energy expenditure and food intake. Diabetologia 56:2297-2307. https://doi.org/10.1007/s00125-013-2987-9
- Kenwood BM, Weaver JL, Bajwa A, Poon IK, Byrne FL, Murrow BA, Calderone JA, Huang L, Divakaruni AS, Tomsig JL, Okabe K, Lo RH, Cameron Coleman G, Columbus L, Yan Z, Saucerman JJ, Smith JS, Holmes JW, Lynch KR, Ravichandran KS, Uchiyama S, Santos WL, Rogers GW, Okusa MD, Bayliss DA, Hoehn KL (2013) Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Mol Metab 3:114-123. https://doi.org/10.1016/j.molmet.2013.11.005
- Perry RJ, Kim T, Zhang XM, Lee HY, Pesta D, Popov VB, Zhang D, Rahimi Y, Jurczak MJ, Cline GW, Spiegel DA, Shulman GI (2013) Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metab 18:740-748. https://doi.org/10.1016/j.cmet.2013.10.004
- Perry RJ et al (2015) Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 347:1253-1256. https://doi.org/10.1126/science.aaa0672
- Tao H et al (2014) Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med 20:1263-1269. https://doi.org/10.1038/nm.3699
- Kanemoto N et al (2019) Antidiabetic and cardiovascular beneficial effects of a liver-localized mitochondrial uncoupler. Nat Commun 10:2172. https://doi.org/10.1038/s41467-019-09911-6
- Okamoto T et al (2021) New approach to drug discovery of a safe mitochondrial uncoupler: OPC-163493. ACS Omega 6:16980-16988. https://doi.org/10.1021/acsomega.1c0199
- Inoue Y et al (2022) Preclinical safety profile of a liver-localized mitochondrial uncoupler: OPC-163493. EXCLI J 21:213-235. https://doi.org/10.17179/excli2021-4414
- Haasio K et al (2001) Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J Neural Transm 108:79-91. https://doi.org/10.1007/s007020170099
- Fabbri M et al (2022) COMT inhibitors in the management of Parkinson's disease. CNS Drugs 36:261-282. https://doi.org/10.1007/s40263-021-00888-9
- Haasio K et al (2002) Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur J Pharmacol 453:21-26. https://doi.org/10.1016/s0014-2999(02)02383-x
- Heytler PG, Prichard WW (1962) A new class of uncoupling agents-carbonyl cyanide phenylhydrazones. Biochem Biophys Res Commun 7:272-275. https://doi.org/10.1016/0076-6879(79)55060-5
- Heytler PG (1979) Uncouplers of oxidative phosphorylation. Methods Enzymol 55:462-472 https://doi.org/10.1016/0076-6879(79)55060-5
- Park KS (2002) FCCP depolarizes plasma membrane potential by activating proton and Na+ currents in bovine aortic endothelial cells. Pflugers Arch 443:344-352. https://doi.org/10.1007/s004240100703
- Georgakopoulos ND, Wells G, Campanella M (2017) The pharmacological regulation of cellular mitophagy. Nat Chem Biol 13:136-146. https://doi.org/10.1038/nchembio.2287
- Kane MS et al (2018) Current mechanistic insights into the CCCP-induced cell survival response. Biochem Pharmacol 148:100-110. https://doi.org/10.1016/j.bcp.2017.12.018
- Wu M et al (2007) Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 292:125-136. https://doi.org/10.1152/ajpcell.00247.2006
- Mythili MD et al (2004) Effect of streptozotocin on the ultrastructure of rat pancreatic islets. Micro Res Tech 63:274-278. https://doi.org/10.1002/jemt.20039
- Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:537-546 https://doi.org/10.33549/physiolres.930111
- Maronpot RR, Boorman GA, Gaul BW (1999) Liver and gallbladder. In: Pathology of the mouse. Cache River Press, pp 119-183
- Peiris LDC et al (2019) 1,3-Dinitrobenze-induced genotoxicity through altering nuclear integrity of diploid and polyploidy germ cells. Dose Response. https://doi.org/10.1177/1559325819876760
- Li Y et al (2014) Scrotal heat induced the Nrf2-driven antioxidant response during oxidative stress and apoptosis in the mouse testis. Acta Histochem 116:883-890. https://doi.org/10.1016/j.acthis.2014.02.008
- Kheradmand A, Dezfoulian O, Alirezaei M (2012) Ghrelin regulates Bax and PCNA but not Bcl-2 expressions following scrotal hyperthermia in the rat. Tissue Cell 44:308-315. https://doi.org/10.1016/j.tice.2012.04.009
- Everds NE et al (2013) Interpreting stress responses during routine toxicity studies: a review of the biology, impact, and assessment. Toxicol Pathol 41:560-614. https://doi.org/10.1177/0192623312466452
- Haasio K et al (2002) Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J Neural Transm 109:1391-1401. https://doi.org/10.1007/s00702-002-0748-x
- Male rats treated orally with 2,4-dinitrophenol in the 28-day repeat dose toxicity test [online]. Research Institute for Animal Science in Biochemistry and Toxicology. https://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF51-28-5b.pdf [Figures and Tables in English]
- Tolcapone, pharmacology review part 1 [online]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20697_Tasmar_pharmr_P1.pdf